Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.1.1.44 - phosphogluconate dehydrogenase (NADP+-dependent, decarboxylating)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
Slow-binding inhibition of 6-phosphogluconate dehydrogenase by zinc ion.
Anemia
6-Phosphogluconate dehydrogenase deficiency in an Italian family.
Anemia, Hemolytic
Combined G-6PD and 6-PGD deficiency in a Hindu boy.
Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin.
beta-Thalassemia
[Aspects of the decrease of some enzyme activities in erythrocytes of subjects with beta-thalassemia]
Breast Neoplasms
Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation.
Oxidative Pentose Phosphate Pathway Enzyme 6-Phosphogluconate Dehydrogenase Plays a Key Role in Breast Cancer Metabolism.
Carcinogenesis
6PGD Upregulation is Associated with Chemo- and Immuno-Resistance of Renal Cell Carcinoma via AMPK Signaling-Dependent NADPH-Mediated Metabolic Reprograming.
Discovery of Ebselen as an Inhibitor of 6PGD for Suppressing Tumor Growth.
Carcinoma
6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met.
6PGD Upregulation is Associated with Chemo- and Immuno-Resistance of Renal Cell Carcinoma via AMPK Signaling-Dependent NADPH-Mediated Metabolic Reprograming.
Pneumococcal 6-phosphogluconate-dehydrogenase, a putative adhesin, induces protective immune response in mice.
Carcinoma, Hepatocellular
6PGD inhibition sensitizes hepatocellular carcinoma to chemotherapy via AMPK activation and metabolic reprogramming.
Carcinoma, Renal Cell
6PGD Upregulation is Associated with Chemo- and Immuno-Resistance of Renal Cell Carcinoma via AMPK Signaling-Dependent NADPH-Mediated Metabolic Reprograming.
Chemical and Drug Induced Liver Injury
[Catalytic properties of 6-phosphogluconate dehydrogenase from rat liver in normal state and during toxic hepatitis]
Glioblastoma
Tyrosine phosphorylation activates 6-phosphogluconate dehydrogenase and promotes tumor growth and radiation resistance.
Glioma
Tyrosine phosphorylation activates 6-phosphogluconate dehydrogenase and promotes tumor growth and radiation resistance.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
6-Phosphogluconate dehydrogenase deficiency in an Italian family.
Combined G-6PD and 6-PGD deficiency in a Hindu boy.
Using the fluorescence spot test for neonatal screening of G6PD deficiency.
Glucosephosphate Dehydrogenase Deficiency
6-Phosphogluconate dehydrogenase deficiency in an Italian family.
Using the fluorescence spot test for neonatal screening of G6PD deficiency.
Hypothyroidism
Changes of activity and kinetics of certain liver and heart enzymes of hypothyroid and T(3)-treated rats.
Infections
Cloning, expression and characterization of a cell wall surface protein, 6-phosphogluconate-dehydrogenase, of Streptococcus suis serotype 2.
Vaccination with Streptococcus suis serotype 2 recombinant 6PGD protein provides protection against S. suis infection in swine.
Iron Overload
In vitro and in vivo effects of iron on the expression and activity of glucose 6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, and glutathione reductase in rat spleen.
Stimulation of gene expression and activity of antioxidant related enzyme in Sprague Dawley rat kidney induced by long-term iron toxicity.
Leishmaniasis
Admixture and relationships of the population of Jacobina, Bahia, Brazil.
Leishmaniasis, Visceral
[The identification of Leishmania isolates obtained from patients and dogs with visceral leishmaniasis in the Turkmen SSR]
Leprosy
Genetic markers and leprosy in South African negroes: Part II. Erythrocyte enzyme polymorphisms.
The genetics of leprosy.
Leukemia
Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth.
Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin.
Lung Neoplasms
Glycolytic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescence.
Inhibition of 6-phosphogluconate Dehydrogenase Reverses Cisplatin Resistance in Ovarian and Lung Cancer.
YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation.
Malaria
Erythrocyte G-6-PD and 6-PGD genetic polymorphisms in South African Negroes, with a note on G-6-PD and the malaria hypothesis.
Genetic markers and malaria. Observations in Gujarat, India.
Neoplasm Metastasis
Physcion and Physcion 8-O-?-D-glucopyranoside: Natural Anthraquinones with Potential Anti-cancer Activities.
Neoplasms
1-Hydroxy-8-methoxy-anthraquinon Reverses Cisplatin Resistance by Inhibiting 6PGD in Cancer Cells.
6-Phosphogluconate dehydrogenase fuels multiple aspects of cancer cells: From cancer initiation to metastasis and chemoresistance.
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met.
A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth.
Blockade of 6-phosphogluconate dehydrogenase generates CD8+ effector T cells with enhanced anti-tumor function.
Discovery of Ebselen as an Inhibitor of 6PGD for Suppressing Tumor Growth.
Evidence for a direct crosstalk between malic enzyme and the pentose phosphate pathway via structural interactions.
Glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase activities in normal canine mammary gland and in mammary tumours and their correlation with oestrogen receptors.
Glycolytic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescence.
Inhibition of 6-phosphogluconate Dehydrogenase Reverses Cisplatin Resistance in Ovarian and Lung Cancer.
Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth.
Modification of the hexokinase activity in the red blood cells of subjects with differentiated adenocarcinoma.
Oxidative Pentose Phosphate Pathway Enzyme 6-Phosphogluconate Dehydrogenase Plays a Key Role in Breast Cancer Metabolism.
Tyrosine phosphorylation activates 6-phosphogluconate dehydrogenase and promotes tumor growth and radiation resistance.
YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation.
Neurilemmoma
Characterization of rat schwannoma-Schwann cell hybrids.
phosphogluconate dehydrogenase (nadp+-dependent, decarboxylating) deficiency
6-Phosphogluconate dehydrogenase deficiency in an Italian family.
Combined G-6PD and 6-PGD deficiency in a Hindu boy.
Prostatic Neoplasms
A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth.
Seizures
The calculation of the cytoplasmic free [NADP+]/[NADPH] ratio in brain: effect of electroconvulsive seizure.
Starvation
Long-term effects of starvation-refeeding in the rat.
Regulation of glucose-6 phosphate dehydrogenase and 6-phosphogluconate dehydrogenase in the meal-fed rat.
[Intensity of pentose phosphate metabolism of carbohydrates in various brain areas in normal and starved animals]
Uterine Cervical Neoplasms
Inhibiting 6-phosphogluconate dehydrogenase enhances chemotherapy efficacy in cervical cancer via AMPK-independent inhibition of RhoA and Rac1.